Organisation paid for research Program year 2025 Source: CMS Open Payments

Neurology Associates PA

Neither a doctor nor a teaching hospital

Research payments

$8,124,282

599 payments

Through program year 2025, Neurology Associates PA is reported as receiving $8,124,282 in research payments, across 599 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,505,006 159
2024 Research $1,367,599 133
2023 Research $1,355,446 77
2022 Research $1,184,882 53
2021 Research $1,447,170 60
2020 Research $687,620 49
2019 Research $576,559 68

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $3,380,638 106 payments
  2. Novartis Pharmaceuticals Corporation $1,979,081 13 payments
  3. F. Hoffmann-La Roche AG $1,144,466 175 payments
  4. Genzyme Corporation $912,185 88 payments
  5. Argenx US, Inc. $153,443 46 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $138,933 27 payments
  7. Amneal Pharmaceuticals LLC $68,927 15 payments
  8. Adamas Pharmaceuticals, Inc. $64,287 25 payments
  9. ITI, Inc. $50,598 20 payments
  10. AbbVie, Inc. $40,814 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ocrelizumab RMS High Dose Study $968,140 18 payments
  2. Ocrelizumab in Patients With RMS $770,899 25 payments
  3. Ensemble $727,361 17 payments
  4. Evaluation of Fenebrutinib in RMS Patients $535,662 24 payments
  5. Ocrelizumab SC Phase III $517,722 15 payments
  6. An Open Label Single Arm Multi Center Extension Study Evaluating Long Term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis $442,948 1 payment
  7. AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes $433,761 2 payments
  8. A Pilot Open-Label, Randomized, Multi-Center, Parall El-Arm, of Acute VS Delay Ofatumumab Treatment D Uring An Acute Multiple Sclerosis Relapse $427,844 2 payments
  9. A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate Or Fingolimod Therapy $413,284 2 payments
  10. A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis $412,348 27 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record